Chargement en cours...

Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival

Immune checkpoint therapy has failed to demonstrate meaningful clinical benefit in unselected cases of pancreatic adenocarcinoma (PDAC), but a subset of PDACs are known to upregulate pathways involved in acquired immune suppression. Further delineation of immunologic subtypes of PDAC is necessary to...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Immunol Res
Auteurs principaux: Danilova, Ludmila, Ho, Won Jin, Zhu, Qingfeng, Vithayathil, Teena, De Jesus-Acosta, Ana, Azad, Nilofer S., Laheru, Daniel A., Fertig, Elana J., Anders, Robert, Jaffee, Elizabeth M., Yarchoan, Mark
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6548624/
https://ncbi.nlm.nih.gov/pubmed/31043417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0822
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!